Literature DB >> 15173171

Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity.

Xiang Xu1, Jingyue Zhao, Zhen Xu, Baozhen Peng, Qiuhua Huang, Eddy Arnold, Jianping Ding.   

Abstract

Isocitrate dehydrogenases (IDHs) catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate, and regulation of the enzymatic activity of IDHs is crucial for their biological functions. Bacterial IDHs are reversibly regulated by phosphorylation of a strictly conserved serine residue at the active site. Eukaryotic NADP-dependent IDHs (NADP-IDHs) have been shown to have diverse important biological functions; however, their regulatory mechanism remains unclear. Structural studies of human cytosolic NADP-IDH (HcIDH) in complex with NADP and in complex with NADP, isocitrate, and Ca2+ reveal three biologically relevant conformational states of the enzyme that differ substantially in the structure of the active site and in the overall structure. A structural segment at the active site that forms a conserved alpha-helix in all known NADP-IDH structures assumes a loop conformation in the open, inactive form of HcIDH; a partially unraveled alpha-helix in the semi-open, intermediate form; and an alpha-helix in the closed, active form. The side chain of Asp279 of this segment occupies the isocitrate-binding site and forms hydrogen bonds with Ser94 (the equivalent of the phosphorylation site in bacterial IDHs) in the inactive form and chelates the metal ion in the active form. The structural data led us to propose a novel self-regulatory mechanism for HcIDH that mimics the phosphorylation mechanism used by the bacterial homologs, consistent with biochemical and biological data. This mechanism might be applicable to other eukaryotic NADP-IDHs. The results also provide insights into the recognition and specificity of substrate and cofactor by eukaryotic NADP-IDHs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15173171     DOI: 10.1074/jbc.M404298200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  150 in total

1.  Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.

Authors:  Zachary J Reitman; Sergey A Sinenko; Eric P Spana; Hai Yan
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

2.  Computational tools for the interactive exploration of proteomic and structural data.

Authors:  John H Morris; Elaine C Meng; Thomas E Ferrin
Journal:  Mol Cell Proteomics       Date:  2010-06-04       Impact factor: 5.911

3.  Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.

Authors:  Avaniyapuram Kannan Murugan; Ermal Bojdani; Mingzhao Xing
Journal:  Biochem Biophys Res Commun       Date:  2010-02-18       Impact factor: 3.575

Review 4.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

5.  Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.

Authors:  Qian Zhao; James R Manning; James Sutton; Abran Costales; Martin Sendzik; Cynthia M Shafer; Julian R Levell; Gang Liu; Thomas Caferro; Young Shin Cho; Mark Palermo; Gregg Chenail; Julia Dooley; Brian Villalba; Ali Farsidjani; Jinyun Chen; Stephanie Dodd; Ty Gould; Guiqing Liang; Kelly Slocum; Minying Pu; Brant Firestone; Joseph Growney; Tycho Heimbach; Raymond Pagliarini
Journal:  ACS Med Chem Lett       Date:  2018-06-11       Impact factor: 4.345

Review 6.  Impact of the Protein Data Bank on antineoplastic approvals.

Authors:  John D Westbrook; Rose Soskind; Brian P Hudson; Stephen K Burley
Journal:  Drug Discov Today       Date:  2020-02-14       Impact factor: 7.851

7.  Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.

Authors:  Jelena Lazovic; Horacio Soto; David Piccioni; Jerry R Lou; Sichen Li; Leili Mirsadraei; William Yong; Robert Prins; Linda M Liau; Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Whitney B Pope
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

8.  Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process.

Authors:  Shigeo Ohba; Joydeep Mukherjee; Tor-Christian Johannessen; Andrew Mancini; Tracy T Chow; Matthew Wood; Lindsey Jones; Tali Mazor; Roxanne E Marshall; Pavithra Viswanath; Kyle M Walsh; Arie Perry; Robert J A Bell; Joanna J Phillips; Joseph F Costello; Sabrina M Ronen; Russell O Pieper
Journal:  Cancer Res       Date:  2016-10-06       Impact factor: 12.701

9.  A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation.

Authors:  Suneel Deepak Kamath; Xiaoqi Lin; Aparna Kalyan
Journal:  Oncologist       Date:  2018-10-23

10.  Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds.

Authors:  Fangrui Wu; Hong Jiang; Baisong Zheng; Mari Kogiso; Yuan Yao; Chao Zhou; Xiao-Nan Li; Yongcheng Song
Journal:  J Med Chem       Date:  2015-08-26       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.